AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36828719
Drug: Separate Administration
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate Administration of QIV and PCV20
Trial: 36829104
Drug: Propofol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (0.5 mg·kg)
Trial: 36829154
Drug: Iruplinalkib 180
RxNorm normalized name: Iruplinalkib
DrugBank: Iruplinalkib (DB17494)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iruplinalkib 180 mg orally once daily for a 21-day cycle with a 7-day lead-in phase at 60 mg orally once daily.
Trial: 36830825
Drug: Frameless CyberKnife
RxNorm normalized name: OCTINOXATE 2.0 mL in 100 mL TOPICAL CREAM [TRACELESS SKIN RESPONSIVE TINT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frameless CyberKnife SRS, doses of 70 to 105 Gy delivered in a single fraction.
Trial: 36830825
Drug: Frameless CyberKnife
RxNorm normalized name: OCTINOXATE 2.0 mL in 100 mL TOPICAL CREAM [TRACELESS SKIN RESPONSIVE TINT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frameless CyberKnife SRS, doses equal to or less than 85 Gy.
Trial: 36830825
Drug: Frameless CyberKnife
RxNorm normalized name: OCTINOXATE 2.0 mL in 100 mL TOPICAL CREAM [TRACELESS SKIN RESPONSIVE TINT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frameless CyberKnife SRS, doses of 95 and 100 Gy.
Trial: 36830825
Drug: Frameless CyberKnife
RxNorm normalized name: OCTINOXATE 2.0 mL in 100 mL TOPICAL CREAM [TRACELESS SKIN RESPONSIVE TINT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frameless CyberKnife SRS, doses below 90 Gy.
Trial: 36833192
Drug: CAH-X treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAH-X treatment
Trial: 36834367
Drug: Epidural Steroid
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural Steroid Injection through a transforaminal approach (ESI TF)
Trial: 36840749
Drug: Everolimus 5
RxNorm normalized name: everolimus 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 5 mg QD and Sorafenib 200 mg BID (intermittent schedule)
Trial: 36840749
Drug: Intermittent dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent dosing schedules
Trial: 36840749
Drug: EVE 10
RxNorm normalized name: Carprieve 100 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EVE 10 mg QD and SOR 400 mg BID (intermittent schedules)
Trial: 36840749
Drug: Dose reductions
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose reductions
Trial: 38051750
Drug: Dose-limiting toxicities
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-limiting toxicities
Trial: 36841318
Drug: Goreisan at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goreisan at a dose of 7.5 g daily on top of usual care
Trial: 36841360
Drug: Biologic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologic treatment eligibility assessment
Trial: 36841360
Drug: Oral corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral corticosteroids (OCS) use
Trial: 36841502
Drug: BCG vaccine
RxNorm normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG vaccine (Moreau or Moscow strains)
Trial: 36841502
Drug: Moreau strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moreau strain of BCG vaccine
Trial: 36841540
Drug: Durvalumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (10 mg/kg intravenously every 2 weeks for up to 1 year)
Trial: 36841762
Drug: Combination (exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination (exercise + liraglutide)
Trial: 36841790
Drug: Probiotics (Peifeikang,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (Peifeikang, Live Combined Bifidobacterium, 210 mg per capsule, twice a day, four capsules each time)
Trial: 36841794
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline and placebo capsules
Trial: 36842439
Drug: Hyperfractionation (65
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperfractionation (65 Gy in 54 fractions, given twice daily with an interfractional time interval of at least 6 h)
Trial: 36842451
Drug: Sugar-sweetened beverages
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar-sweetened beverages (SSBs) at high doses (≥20%E or 100 g/d)
Trial: 36842451
Drug: Fruits at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruits at lower doses (≤10%E or 50 g/d)
Trial: 36842849
Drug: relmacabtagene autoleucel
RxNorm normalized name: relmacabtagene autoleucel
DrugBank: Relmacabtagene autoleucel (DB18979)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: relmacabtagene autoleucel (relma-cel) infusion after lymphodepletion chemotherapy
Trial: 36842886
Drug: AKS-452 (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AKS-452 (90 µg single dose)
Trial: 36842886
Drug: AKS-452 (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AKS-452 (two 45 µg doses 28 days apart)
Trial: 36842964
Drug: High-dose tandospirone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose tandospirone (60 mg/d)
Trial: 36842964
Drug: Low-dose tandospirone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose tandospirone (30 mg/d)
Trial: 36843239
Drug: CPAP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP therapy for 3 months
Trial: 36845050
Drug: Oral ketone
RxNorm normalized name: Ketonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ketone ester (395 mg/kg)
Trial: 36845633
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care treatment (maximal safe resection and postoperative chemoradiotherapy with 60 Gy/30 fr and concurrent/adjuvant temozolomide)
Trial: 36845705
Drug: Pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200 mg IV every 3 weeks) and escalating doses of IL-2 (6,000 or 60,000 or 600,000 IU/kg IV bolus every 8 hours up to 14 doses per cycle)
Trial: 36845705
Drug: High-dose IL-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose IL-2 therapy in combination with pembrolizumab
Trial: 36847333
Drug: Daily blueberry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily blueberry consumption for 12 weeks
Trial: 36847952
Drug: GLP-1 receptor
RxNorm normalized name: GLP-1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 receptor agonist (GLP-1RA)
Trial: 36848061
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy (CT), Mindfulness-based stress reduction (MBSR), Behavior therapy (BT)
Trial: 36848113
Drug: Intranasal mometasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal mometasone (INC group) - 1 application per nostril, once per day for 12 weeks
Trial: 36848113
Drug: 3-mL sodium
RxNorm normalized name: glycopyrronium
DrugBank: Glycopyrronium (DB00986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-mL sodium chloride (NaCl), 0.9%, solution in a nasal nebulizer once a day for 12 weeks (control group)
Trial: 36848311
Drug: Corticosteroids (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids (administered to 18 patients, 19% of TMP-SMZ group)
Trial: 36848311
Drug: TMP-SMZ treatment
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMP-SMZ treatment
Trial: 36848639
Drug: Pegcetacoplan 1080
RxNorm normalized name: pegcetacoplan 1080 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegcetacoplan 1080 mg subcutaneously twice weekly for 26 weeks
Trial: 36848897
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation along with oral rehydration solution (ORS)
Trial: 38685922
Drug: Intensive non-surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive non-surgical treatment
Trial: 36849161
Drug: Micro-particle curcumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micro-particle curcumin (90 mg/day)
Trial: 36849205
Drug: Adjunctive triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjunctive triamcinolone acetonide (TA)
Trial: 36849212
Drug: GIP infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GIP infusion (16 pmol/kg/min)
Trial: 36849212
Drug: Semaglutide injections
RxNorm normalized name: semaglutide Injectable Product
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Semaglutide injections (0.5 mg once-weekly)
Trial: 36849212
Drug: Continuous placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous placebo (subcutaneous)
Trial: 36849797
Drug: onabotulinumtoxinA (onabotA)
RxNorm normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: onabotulinumtoxinA (onabotA) injections
Trial: 36849838
Drug: Inactivated COVID-19
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated COVID-19 vaccine (two-dose vaccination)
Trial: 36849838
Drug: Healthy controls
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy controls (two-dose vaccination)
Trial: 36849955
Drug: Single drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single drug control (either Chidamide or Cladribine)
Trial: 36849969
Drug: Masitinib 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Masitinib 4.5 mg/kg/day
Trial: 36849969
Drug: Masitinib 6.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Masitinib 6.0 mg/kg/day (titrated)
Trial: 36849990
Drug: Real bihemispheric
RxNorm normalized name: REAL FOODS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real bihemispheric tDCS (20 min, 2 mA, during task practice twice daily for 20 sessions in two weeks)
Trial: 36851177
Drug: WIV04 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WIV04 vaccine (5μg of inactivated SARS-CoV-2 virion adsorbed into aluminum hydroxide in a 0.5 mL aqueous suspension)
Trial: 36851177
Drug: HB02 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HB02 vaccine (4μg of inactivated SARS-CoV-2 virion adsorbed into aluminum hydroxide in a 0.5 mL aqueous suspension)
Trial: 36851196
Drug: CV0501 mRNA-based
RxNorm normalized name: mRNA-3705
DrugBank: mRNA-3705 (DB17668)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CV0501 mRNA-based Omicron COVID-19 vaccination (specific dosage and duration not mentioned)
Trial: 36851196
Drug: Bivalent vaccine
RxNorm normalized name: PAPILLOMAVIRUS BIVALENT VACCINE INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent vaccine formulations (specific dosage and duration not mentioned)
Trial: 36851204
Drug: 20 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 µg + 5 µg vaccine formulation
Trial: 36851204
Drug: 20 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 µg + 20 µg vaccine formulation
Trial: 36851662
Drug: ChAdOx1 nCoV-19
RxNorm normalized name: ChAdOx1 nCoV-19
DrugBank: AstraZeneca COVID-19 Vaccine (DB15656)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAdOx1 nCoV-19 vaccine with previous infection
Trial: 36852100
Drug: Guided relaxation
RxNorm normalized name: Relax-DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided relaxation intervention group (video sessions ranging from 2 to 20 min each viewed daily over 5 weeks)
Trial: 36852107
Drug: Sofosbuvir plus
RxNorm normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sofosbuvir plus velpatasvir (SOF/VEL) 400/100 mg once daily for 8 weeks
Trial: 36852705
Drug: Linerixibat 40
RxNorm normalized name: LINERIXIBAT
DrugBank: Linerixibat (DB11729)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linerixibat 40 mg BID
Trial: 36852998
Drug: COVID-HIGIV 100
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-HIGIV 100 mg/kg
Trial: 36852998
Drug: COVID-HIGIV 200
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-HIGIV 200 mg/kg
Trial: 36852998
Drug: COVID-HIGIV 400
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-HIGIV 400 mg/kg
Trial: 36853611
Drug: Combined drug
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined drug approach with standard of care (static cold storage)
Trial: 36853611
Drug: Combined drug
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined drug approach
Trial: 36853612
Drug: Intravenous vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vitamin C (1.5 g), thiamine hydrochloride (100 mg), and hydrocortisone sodium succinate (50 mg) every 6 hours for 96 hours
Trial: 36853612
Drug: Intravenous vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vitamin C, thiamine, and hydrocortisone
Trial: 36854071
Drug: Dinutuximab beta
RxNorm normalized name: dinutuximab beta
DrugBank: Dinutuximab (DB09077)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dinutuximab beta (DB) plus subcutaneous interleukin-2 (scIL2) after haplo-SCT
Trial: 36854570
Drug: Bispecific antibody
RxNorm normalized name: Bispecific antibody 520c9x22
DrugBank: MDX-210 (DB17250)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bispecific antibody (bsAb)-KN046
Trial: 36854583
Drug: Internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive behavioural therapy for 12 weeks
Trial: 36854604
Drug: Afatinib combined
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Afatinib combined with GEMOX chemotherapy (gemcitabine and oxaliplatin)
Trial: 36855089
Drug: Morphine-based analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine-based analgesia
Trial: 36855099
Drug: Tafolecimab 150
RxNorm normalized name: Tafolecimab
DrugBank: Tafolecimab (DB16336)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafolecimab 150 mg Q2W
Trial: 36855099
Drug: Tafolecimab 450
RxNorm normalized name: Tafolecimab
DrugBank: Tafolecimab (DB16336)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafolecimab 450 mg Q4W
Trial: 36855099
Drug: Tafolecimab (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafolecimab (both doses)
Trial: 36855109
Drug: 300,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300,000 IU cholecalciferol followed by 1400 IU cholecalciferol + 500 mg of calcium daily (n = 151)
Trial: 36855160
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous ketamine infusions
Trial: 36855169
Drug: Wangbi granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wangbi granule 12.0 g, three times a day for 12 weeks
Trial: 36855169
Drug: Wangbi placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wangbi placebo 12.0 g, three times a day for 12 weeks
Trial: 36855177
Drug: estradiol treatment
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: estradiol treatment for 3 weeks
Trial: 36855177
Drug: placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo treatment for 3 weeks
Trial: 36855334
Drug: Standard-of-Care Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-Care Treatment
Trial: 36856104
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy selected designed program (Control)
Trial: 36856122
Drug: Oral intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral intake of fermented milk
Trial: 36856280
Drug: Doubled semitendinosus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doubled semitendinosus and gracilis tendon (ST/G) graft
Trial: 36856456
Drug: Novel Dietary
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel Dietary Supplement
Trial: 36856614
Drug: Hydrochlorothiazide 12.5
RxNorm normalized name: hydrochlorothiazide 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 12.5 mg once daily
Trial: 36856617
Drug: Neoadjuvant-adjuvant pembrolizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant-adjuvant pembrolizumab (3 doses before surgery and 15 doses after surgery)
Trial: 36856617
Drug: Adjuvant-only pembrolizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant-only pembrolizumab (200 mg intravenously every 3 weeks for a total of 18 doses)
Trial: 36856701
Drug: Memantine (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine (10-20 mg/day)
Trial: 36856733
Drug: Temozolomide (first-line
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temozolomide (first-line chemotherapy)
Trial: 36856733
Drug: Immune checkpoint
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune checkpoint inhibitors (second-line treatment)
Trial: 36856733
Drug: Tyrosine kinase
RxNorm normalized name: Protein-tyrosine kinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyrosine kinase inhibitors and everolimus
Trial: 36856978
Drug: Topical cyclosporine-A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cyclosporine-A (CsA) 0.1% cationic emulsion (Ikervis) instilled once daily to both eyes from 3-5 weeks pre-HSCT to 12 months post-HSCT
Trial: 36856978
Drug: Topical cyclosporine-A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cyclosporine-A (CsA) 0.1% cationic emulsion (Ikervis)
Trial: 36857053
Drug: Intensive BP
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive BP treatment (SBP target <120 mm Hg)
Trial: 36857058
Drug: Implant-based reconstruction
RxNorm normalized name: CONSTRICTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant-based reconstruction (IBR)
Trial: 36857339
Drug: RELiZORB enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RELiZORB enzyme cartridge used daily with enteral nutrition (EN) for 90 days
Trial: 36857393
Drug: ATG 6.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATG 6.0 mg/kg
Trial: 36857596
Drug: Metformin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin + Aspirin
Trial: 36858257
Drug: Epinephrine infusion
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine infusion at 0.03 mcg/kg/min
Trial: 36858257
Drug: Epinephrine infusion
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine infusion at 0.02 mcg/kg/min
Trial: 36858257
Drug: Epinephrine infusion
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine infusion at 0.01 mcg/kg/min
Trial: 36858257
Drug: Epinephrine infusion
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine infusion (all doses)
Trial: 36858721
Drug: Lenvatinib (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenvatinib (20 mg per day orally in 21-day cycles) plus pembrolizumab (200 mg intravenously every 21 days)
Trial: 36858721
Drug: Sunitinib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (50 mg per day orally, 4 weeks on and 2 weeks off)
Trial: 36858722
Drug: OEPA (vincristine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OEPA (vincristine 1·5 mg/m², etoposide, prednisone, and doxorubicin) without radiotherapy
Trial: 36859316
Drug: Nalmefene 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalmefene 0.25 µg/kg
Trial: 36859467
Drug: Oral triheptanoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral triheptanoin at a dose of 1 g/Kg/day, providing near 35% of total caloric intake.
Trial: 36859467
Drug: Maximum tolerated
RxNorm normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maximum tolerated dose of triheptanoin at 45% of daily caloric intake for each age group.
Trial: 36859467
Drug: Triheptanoin treatment.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triheptanoin treatment.
Trial: 36860319
Drug: Cetuximab-based treatment
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab-based treatment regimen
Trial: 36861013
Drug: Arbaclofen extended-release
RxNorm normalized name: Baclofen
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arbaclofen extended-release 80 mg/day
Trial: 36861013
Drug: Arbaclofen extended-release
RxNorm normalized name: Baclofen
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arbaclofen extended-release
Trial: 36861188
Drug: Apixaban 2.5
RxNorm normalized name: apixaban 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban 2.5 mg (single dose) administered using two pediatric formulations: 0.1 mg sprinkle capsule (age <28 days) and 0.4 mg/ml solution (age 28 days to <18 years); dose range 1.08-2.19 mg/mL.